Nicotine Polacrilex Market Scope
Nicotine Polacrilex is the nicotine that is bound to an ion-exchange resin-like polymethacrylic acid. It is added to gums and hard lozenges that are used in nicotine replacement therapy in smoking cessation. Using the polymer as a delivery system maximizes the amount of nicotine that is released and absorbed by the oral mucosa. 80 to 90 percent of the nicotine released from the gums is absorbed by the mouth. Nicotine Polacrilex is the main ingredient in tobacco products. Nicotine Polacrilex Gum and Lozenges are medicinal products that are used to aid in smoking cessation in adults. Using a controlled amount of Polacrilex nicotine will help reduce withdrawal symptoms while you quit smoking. This drug can help you quit smoking by substituting the nicotine in cigarettes. The nicotine in tobacco is an important part of cigarette addiction. When you stop smoking, your nicotine levels drop swiftly. This drop can cause withdrawal symptoms such as tobacco cravings, nervousness, irritability, headache, weight gain, and difficulty concentrating. The amount of nicotine polacrilex in a used or unused lozenge or piece of gum can be fatal to a child who accidentally suckles or chews on it. Therefore, in such conditions, you should consult an emergency doctor. Overdose symptoms can include severe dizziness, nausea, vomiting, diarrhea, weakness, and fast heart rate.
The market study is being classified by Type (High Purity and Low Purity), by Application (Nicotine Polacrilex Gum, Nicotine Polacrilex Lozenge and Other) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that European Vendors will contribute to the maximum growth of Global Nicotine Polacrilex market throughout the predicted period.
BGP Healthcare (India), GlaxoSmithKline (United Kingdom), Cambrex Corporate (United States), Nicobrand (United Kingdom), Glenmark Pharmaceuticals (India), Alchem International (India), Dixie Chemical (United States), Fertin Pharma (Denmark), Laboratorios Haymann (Uruguay) and Mallinckrodt (United Kingdom) are some of the key players profiled in the study. Additionally, the Vendors which are also part of the research are Siegfried Holding (Switzerland) and Porton Pharma Solutions (China).
AdvanceMarketAnalytics has segmented the market of Global Nicotine Polacrilex market by Type, Application and Region.
On the basis of geography, the market of Nicotine Polacrilex has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
On May 21, 2019, GlaxoSmithKline launched new Nicorette Coated Ice Mint Lozenges, the first-ever coated lozenge, in partnership with the Dale Earnhardt Jr. and In November 2017, Glenmark Pharmaceuticals launched a nicotine replacement therapy gum named Kwitz
A permissive nicotine regulatory policy would allow sales of pharmaceutical grade nicotine delivery systems to adults without a prescription. The FDA could suggest warnings appropriate for classes of products and delivery system constituents. Manufacturers would accurately label contents and would be legally liable for undisclosed harms caused by the delivery system and constituents other than nicotine, as with any pharmaceutical product. The FDA could prohibit inherently risky delivery systems and would undertake a full, traditional review of nicotine systems that give users a faster or higher peak arterial level of nicotine than cigarettes. The FDA would also review additives intended to provide antidepressant or other effects familiar to smokers. Youth marketing and access would be illegal, as with cigarettes.
- An increasing number of people quitting smoking with the aid from medications
- The rise in the number of people willing to quit smoking
- Increased awareness about the fatal diseases caused by smoking like lung cancer, heart attacks, and chronic obstructive pulmonary disease.
- The government nods for the purchase of nicotine gums without a prescription
- Increased government-sponsored projects and help centers worldwide for helping cigarettes addicted people quit smoking
- Side Effects Associated with the Long Term Usage of Nicotine Polacrilex
- The Availability of Other Smoking Cessation Products
- Lack of Awareness Regarding Nicotine Polacrilex
Key Target Audience
Providers of Nicotine Polacrilex, End-Users, Potential Investors, Government Bodies, Market Research Firms and Others
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase